Tianjin TEDA Biomedical Engineering Company Limited reported a decisive turnaround for the six months ended 30 June 2026, as brisk expansion of its artificial-intelligence (AI) health operations offset weakness in traditional fertiliser sales.
Revenue and Profitability • Consolidated revenue rose 30.75% year on year to RMB 296.03 million, led by the AI life-and-health segment, whose sales more than doubled to RMB 106.37 million. Fertiliser sales edged up 3.65% to RMB 189.67 million. • Gross profit surged 141.40% to RMB 33.36 million, boosting the gross margin to 11.27% from 6.10% a year earlier. • The Group recorded profit attributable to equity holders of RMB 10.21 million, compared with a loss of RMB 6.43 million in 1H25. Basic EPS reached RMB 0.048 cent versus a loss per share of RMB 0.317 cent. • The Board declared no interim dividend.
Cost and Expense Profile • Selling and distribution expenses fell 19.09% to RMB 3.20 million amid tighter cost control. • R&D and administrative expenses declined 20.39% to RMB 13.18 million, partly reflecting capitalisation of qualifying development outlays. • Finance costs decreased 22.30% to RMB 1.53 million as borrowings were broadly stable and average interest rates eased.
Cash Flow and Balance Sheet • Operating activities generated net cash of RMB 37.50 million, reversing the RMB 98.40 million outflow posted in the prior-year period. • Period-end cash and bank balances more than doubled to RMB 65.30 million. • Total assets stood at RMB 443.84 million, while total liabilities reached RMB 415.04 million, placing the asset-to-debt ratio at 0.94 (31 December 2025: 0.99). • Net assets improved to RMB 28.80 million from RMB 2.73 million six months earlier; gearing (bank borrowings to total assets) narrowed to 0.22 from 0.37.
Operational Highlights • The AI life-and-health division, anchored by the proprietary “Xihe No.1” medical large-language model developed with Peking University Third Hospital, contributed revenue of about RMB 100 million and net profit of roughly RMB 14 million. • City-level public-data platforms in Yinchuan and Xiamen began deployment, stimulating demand for the Group’s supporting software and hardware services. • Fertiliser volumes declined amid high raw-material costs and intense industry competition, prompting an ongoing resource shift toward AI healthcare initiatives.
Management Update On 31 March 2026, the Board appointed Ms Lynn Li as Joint Chief Executive Officer and redesignated Ms Sun Li as Joint Chief Executive Officer, while Ms Sun continues to serve as Board Chair. On 3 June 2026, Mr Xia Alan Zhe was redesignated from Executive Director to Non-Executive Director.
Outlook Management intends to accelerate national rollout of the “Xihe No.1” model and expand AI-enabled healthcare applications, while further scaling city-data platforms such as Yinchuan’s “One Cloud, One Lake, One Platform”. The fertiliser unit will remain under optimisation as strategic focus intensifies on AI medical technology solutions.